Catalent Launches New Business Unit - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Catalent Launches New Business Unit
The new unit aligns existing modified-release and medication-delivery businesses of the company.


The CDMO Catalent Pharma Solutions has created a new business unit, Advanced Delivery Technologies, which aligns the company’s existing modified-release and medication-delivery businesses, including biologics technologies and capabilities.

The new business unit will operate eight development and manufacturing facilities globally. These facilities include: those for fast-dissolve technologies at Swindon, United Kingdom; controlled-release technologies in Winchester, Kentucky, which is currently undergoing a major expansion, the recently expanded Schorndorf, Germany site; the advanced drug-development center in Somerset, New Jersey, the new biologics center of excellence in Madison, Wisconsin; advanced aseptic production in Woodstock, Illinois; and prefilled syringe facilities in Brussels, Belgium and Limoges, France.

The new business unit of Advanced Delivery Technologies complements existing business units for softgel technologies and development and Development and clinical services.

Barry Littlejohns has been named president of the new business unit. He has more than 25 years of experience in the drug-delivery industry spanning oral dose forms, parenteral delivery and biologics. “Our industry is facing tough challenges with increasingly difficult molecules, requiring more sophisticated development expertise, delivery technologies and supply capabilities to optimize bioavailability, therapeutic profiles and clinical outcomes,” he said in a company press release.“By bringing together talent and expertise from two proven teams, with our extensive intellectual property, technology and manufacturing platforms, we expect to partner with innovators around the world to deliver the most innovative, advanced and effective solutions to help bring more products to market faster and improve the efficacy of their treatments."

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here